EquityFlow › Companies › LoQus23 Therapeutics

LoQus23 Therapeutics

Biotech · Cambridge, GB

Developing small-molecule drugs for triplet-repeat-expansion diseases.

Funding history

DateRoundAmount
Oct 2024Series A
LoQus23 Therapeutics, a Cambridge biotech targeting triplet-repeat diseases, raised a GBP35M Series A led by Forbion.
$45M

Investors

Forbion

Similar companies in Biotech

ImperagenHaga BiosciencePixelgen TechnologiesGallantChai DiscoverySNIPR BiomeCellbox LabsScope BiosciencesGenLuminaActitheraNUCLIDIUMAnocca
Explore funding flow on EquityFlow →